nimesulide has been researched along with angiotensin ii in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Durie, M; Levy, BI; Silvestre, JS; Tamarat, R | 1 |
| de Champlain, J; Laplante, MA; Wu, R | 1 |
| Mitchell, KD; Mouton, CR; Mullins, JJ; Opay, AL | 1 |
| Mitchell, KD; Mullins, JJ; Patterson, ME | 1 |
| Adams, GN; Bilodeau, ML; Chen, A; Fang, C; Grobe, N; LaRusch, G; Mahdi, F; Morris, M; Nieman, MT; Schmaier, AA; Schmaier, AH; Stavrou, E; Warnock, M; Zhou, Y | 1 |
| Asirvatham-Jeyaraj, N; Fink, GD; King, AJ; Madan, S; Northcott, CA | 1 |
| Alhalabi, O; Antoniak, S; Fang, C; Grobe, N; Mackman, N; Merkulova, A; Schmaier, AH; Stavrou, EX | 1 |
| Cha, SA; Gao, S; Kim, SH; Park, BM | 1 |
| Llinás, MT; López, R; Salazar, E; Salazar, FJ | 1 |
9 other study(ies) available for nimesulide and angiotensin ii
| Article | Year |
|---|---|
Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies, Monoclonal; Benzimidazoles; Biphenyl Compounds; Collagen; Cyclooxygenase 2; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Endothelial Growth Factors; Female; Imidazoles; Isoenzymes; Laminin; Lymphokines; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Prostaglandin-Endoperoxide Synthases; Proteoglycans; Pyridines; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Sulfonamides; Tetrazoles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Cyclooxygenase-2 inhibitors attenuate angiotensin II-induced oxidative stress, hypertension, and cardiac hypertrophy in rats.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiomegaly; Cells, Cultured; Cyclooxygenase Inhibitors; Hypertension; Lactones; Male; Myocardium; NF-kappa B; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2005 |
Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 CYP1A1; Glomerular Filtration Rate; Hypertension, Malignant; Male; Meclofenamic Acid; Rats; Sulfonamides; Vascular Resistance | 2006 |
Renoprotective effects of neuronal NOS-derived nitric oxide and cyclooxygenase-2 metabolites in transgenic rats with inducible malignant hypertension.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Citrulline; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytochrome P-450 CYP1A1; Enzyme Inhibitors; Hypertension, Malignant; Indoles; Kidney; Male; Nitric Oxide Synthase Type I; Rats; Regional Blood Flow; Renin; Sulfonamides; Thiourea; Vasoconstriction | 2008 |
Angiotensin 1-7 and Mas decrease thrombosis in Bdkrb2-/- mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation.
Topics: Angiotensin I; Angiotensin II; Animals; Bleeding Time; Blood Platelets; Bone Marrow Transplantation; Cyclic AMP; Cyclic GMP; Epoprostenol; Immunoblotting; Mice; Mice, 129 Strain; Mice, Knockout; NG-Nitroarginine Methyl Ester; Nitric Oxide; Peptide Fragments; Platelet Aggregation Inhibitors; Platelet Membrane Glycoproteins; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Thrombosis; Time Factors | 2013 |
Cyclooxygenase-1 inhibition attenuates angiotensin II-salt hypertension and neurogenic pressor activity in the rat.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Ganglionic Blockers; Hypertension; Ketoprofen; Male; Membrane Proteins; Norepinephrine; Pyrazoles; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Sulfonamides; Sympathetic Nervous System; Time Factors | 2013 |
Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor.
Topics: Angiotensin II; Animals; Carotid Artery Thrombosis; Epoprostenol; Imidazoles; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Mice; Mice, Knockout; Naphthalenes; Nerve Tissue Proteins; Partial Thromboplastin Time; Peptide Fragments; Prekallikrein; Proto-Oncogene Mas; Proto-Oncogene Proteins; Pyrones; Receptor, Bradykinin B2; Receptors, G-Protein-Coupled; RNA, Messenger; Sirtuin 1; Sulfonamides; Synaptotagmins; Thromboplastin | 2015 |
Attenuation of renovascular hypertension by cyclooxygenase-2 inhibitor partly through ANP release.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiomegaly; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Hypertension, Renovascular; Natriuretic Peptide, Brain; Nitrobenzenes; Rats; Sulfonamides | 2015 |
Renal Effects of Cyclooxygenase Inhibition When Nitric Oxide Synthesis Is Reduced and Angiotensin II Levels Are Enhanced.
Topics: Angiotensin II; Animals; Blood Pressure; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dogs; Female; Glomerular Filtration Rate; Infusions, Intravenous; Male; Meclofenamic Acid; Models, Animal; Natriuresis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Renal Artery; Sulfonamides; Vasoconstriction | 2015 |